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Suspensory ligament injuries are a common injury in sport horses, especially in competing 
dressage horses. Because of the poor healing of chronic recalcitrant tendon injuries, this 
represents a major problem in the rehabilitation of sport horses and often compromises 
the return to the initial performance level. Stem cells are considered as a novel treatment 
for different pathologies in horses and humans. Autologous mesenchymal stem cells 
(MSCs) are well known for their use in the treatment of tendinopathies; however, recent 
studies report a safe use of allogeneic MSCs for different orthopedic applications in 
horses. Moreover, it has been reported that pre-differentiation of MSCs prior to injection 
might result in improved clinical outcomes. For all these reasons, the present case report 
describes the use of allogeneic tenogenically induced peripheral blood-derived MSCs for 
the treatment of a proximal suspensory ligament injury. During conservative management 
for 4 months, the horse demonstrated no improvement of a right front lameness with a 
Grade 2/5 on the American Association of Equine Practitioners (AAEP) scale and a clear 
hypo-echoic area detectable in 30% of the cross sectional area. From 4 weeks after 
treatment, the lameness reduced to an AAEP Grade 1/5 and a clear filling of the lesion 
could be noticed on ultrasound. At 12 weeks (T4) after the first injection, a second intral-
esional injection with allogeneic tenogenically induced MSCs and platelet-rich plasma 
was given and at 4 weeks after the second injection (T5), the horse trotted sound under 
all circumstances with a close to total fiber alignment. The horse went back to previous 
performance level at 32 weeks after the first regenerative therapy and is currently still 
doing so (i.e., 20 weeks later or 1 year after the first stem cell treatment). In conclusion, 
the present case report demonstrated a positive evolution of proximal suspensory liga-
ment desmitis after treatment with allogeneic tenogenically induced MSCs.
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INtroDUctIoN
Suspensory ligament injuries are a major issue in equine ortho-
pedics. It is indicated in both elite and non-elite dressage horses 
to have a higher risk compared to horses undertaking general-
purpose exercise or doing other disciplines (1). Commonly, it is 
the proximal aspect of the suspensory ligament that is affected in 
these sport horses (2).
The limited healing of tendon tissue, with the formation of scar 
tissue, has been attributed to the low number of residing cells in 
relation to the extensive volume of the extracellular matrix. The 
reduced healing capacity of tendons and ligaments is a major prob-
lem in the rehabilitation of sport horses and leads to chronic injuries 
with a poor prognosis (3, 4). Indeed, these tendinous lesions often 
compromise the return of the horse to the initial performance level.
Therapies for suspensory ligament pathologies consist of 
conservative management, regenerative therapies, and surgical 
therapies. Conservative management aims at promoting the 
optimal healing of an acutely damaged tendon by medical treat-
ments, rest, cold applications, corrective shoeing, and controlled 
exercises (5–8). For chronic tendinopathies, eccentric tendon 
training, extracorporeal shockwave therapy, and surgical therapy 
are indicated (8). Surgical therapy consists of a fasciotomy, with 
neurectomy of the deep branch of the palmar or the plantar 
nerve, or a suspensory desmoplasty (surgical fasciotomy and 
splitting) (9–11).
Recent regenerative therapies, containing growth factor-
based therapies and cell therapies, report an improvement of 
tendon healing and reduction of recidives (2, 8, 12). For safety 
(no calcifications) and efficacy (functional recovery) reasons, it 
has been reported that inducing stem cells toward a tenogenic 
phenotype is a valuable alternative for conservative treatments 
(12) and adding platelet-rich plasma (PRP) generates superior 
effects in comparison to both treatments separately for the treat-
ment of degenerative joint disease (13). Moreover, allogeneic 
PRP and cell-based therapies represent a valuable alternative for 
autologous treatments because of the immediate availability and 
ease to use in field circumstances. Indeed, different groups report 
a safe intradermal, intra-articular, and intravenous application of 
allogeneic mesenchymal stem cells (MSCs) in a total of more than 
500 horses in all studies together (13–17). Although several stud-
ies report the safe and effective use of allogeneic MSCs in equine 
tendons (12, 18–20), only limited information on tenogenically 
induced allogeneic MSCs and allogeneic PRP for the treatment 
of chronic tendon lesions is currently available (21).
For all the aforementioned reasons, this case report describes 
the treatment of a chronic recalcitrant proximal suspensory liga-
ment desmitis with allogeneic tenogenically induced peripheral 
blood-derived MSCs in combination with allogeneic PRP.
case DetaILs
History
A 9-year-old, KWPN stallion, intended for dressage work at 
higher level (sub Grand Prix), was diagnosed with a lesion 
at the lateral border of the proximal aspect of the suspensory 
ligament. The horse was treated 4 months ago with non-steroidal 
anti-inflammatory drugs (NSAIDs) and a single intralesional 
injection of PRP combined with a controlled rehabilitation 
program. This consisted of 2  weeks of hand walking and daily 
cooling of the leg with a soft protecting resting bandage during 
the night, followed with 1  week of walk and trot on a straight 
line. Afterwards, gradual walking and trotting exercises were per-
formed for 3 weeks starting with 2 min trot a day with an increase 
of 2 min every 2 days up to 20 min trotting per day. Treatments 
remained clinically and ultrasonographically unresponsive.
clinical examination and Diagnostic 
analgesia
Four months after the initial diagnosis and first treatment pro-
gram, the horse was presented for an orthopedic examination. 
At the initial clinical examination, as well as 4 months later (i.e., 
before the first stem cell injection), the horse showed a right 
front lameness of 2/5 on the American Association of Equine 
Practitioners (AAEP) scale (Table 1). The lameness was consistent 
in degree in straight lines. When trotting on the circle to the left 
on a soft surface, the right front lameness was more pronounced 
with a marked reduced cranial phase of the stride. Passive flexion 
of the lower part of the right front limb exacerbated the lameness.
Several diagnostic anesthesia’s of the right front limb, each 
with 2% Mepivacaine hydrochloride solution, were performed. A 
distal digital nerve block, an abaxial nerve block and a low four 
point nerve block were negative. A nerve block of the deep branch 
of the lateral palmar nerve almost completely abolished the right 
front lameness to a score of 0.5/5 on the AAEP scale.
Diagnostic Imaging
Radiographic Examination
Dorsopalmar, lateromedial, and oblique radiographic projec-
tions of the right proximal metacarpal region were obtained and 
compared with the contralateral limb. No abnormal findings were 
noticed.
Computed Tomography
In mutual agreement with the owner, computed tomography was 
performed in order to further evaluate the palmar aspect of the 
proximal third metacarpal bone (Figure 1A). Contrast angiogra-
phy was not performed in this horse.
Mild to moderate bone remodeling of the palmar third meta-
carpal bone was observed. This was more pronounced medially, 
with the presence of a large osteophyte axially (Figure  1B). 
taBLe 1 | aaep lameness scale.
Grade degree of lameness (on 5)
0 Lameness not perceptible under any circumstances
1 Lameness is difficult to observe and is not consistently apparent, 
regardless of circumstances
2 Lameness is difficult to observe at a walk, or when trotting in a 
straight line, but consistently apparent under certain circumstances
3 Lameness is consistently observable at a trot under all circumstances
4 Lameness is obvious at a walk
5 Lameness produces minimal weight bearing in motion and/or at rest 
or a complete inability to move
taBLe 2 | the scoring system used to evaluate and compare the 
ultrasound images in the present report.
score echogenicity Fiber pattern/
alignment
size of 
ligament
0 Anechoic area (central core 
lesion)
Lacking of parallel 
pattern acute injury 
(hemorrhage), 0–25% 
FA
Enlarged 
width and 
thickness
1 Lesion site starting to fill with 
presence of hypo-echoic 
areas, and moderate diffuse 
decrease in echogenicity
Lacking of nice 
parallel pattern, 
0–25% FA
Enlarged 
width and 
thickness
2 Lesion site gradually filling with 
presence of multiple areas with 
decreased echogenicity
Increased parallel 
pattern, 25–50% FA
Enlarged 
width and 
thickness
3 Demarcation between injured 
and uninjured tendon less 
distinct, hypo-echoic areas are 
remaining
Increased parallel 
pattern, 25–50% FA
Mild enlarged 
width and 
thickness
4 Hardly any demarcation 
between injured and healthy 
tissue, faint signs of hypo-
echoic areas
Close to total fiber 
alignment, 75–100% 
FA
Almost no 
enlarged 
width and 
thickness
5 Echogenicity (almost) identical 
to contralateral ligament
Close to total fiber 
alignment, 75–100% 
FA
No enlarged 
width and 
thickness
Different parameters, such as echogenicity, fiber pattern/alignment (FA) grading, and 
size (width and thickness) of the ligament, were considered and compared to the 
contralateral limb.
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Moreover, a moderate sclerosis at the medial aspect of the proxi-
mopalmar third metacarpal bone was present (Figure 1B).
Ultrasound Examination
A 7.5-MHz linear ultrasound probe was used to evaluate the 
palmar aspect of the right metacarpal region. A complete exami-
nation of the suspensory ligament was performed during each 
ultrasound examination with both transverse and longitudinal 
scans. The scoring system was adapted from a previous study by 
Beerts et al. (21) and can be found in Table 2.
At the proximal aspect of the lateral lobe of the suspensory 
ligament, a focal hypo-echogenic area with an abnormal fiber 
alignment was present and consisted of approximately 30% of the 
cross sectional area of the suspensory ligament. In comparison 
with the clinically sound contralateral limb, the proximal aspect 
of the suspensory ligament was enlarged with a poor demarcation 
of the dorsal margin (Figure 2).
treatment
Four weeks after the computed tomography examination, an 
intralesional injection with allogeneic tenogenically induced 
FIGUre 1 | Longitudinal anatomical section of the proximal 
metacarpus showing the origin of the proximal third interosseus 
muscle (suspensory ligament) over the third metacarpal bone and 
distal carpus. 1 – suspensory ligament; 2 – third metacarpal bone; 3 – deep 
palmar metacarpal vascular anastomosis; 4 – accessory ligament of the deep 
digital flexor tendon; 5 – deep digital flexor tendon; 6 – superficial digital flexor 
tendon; 7 – skin (a). Computer tomography demonstrated a mild to 
moderate bone remodeling (white arrows) and sclerosis (black arrows) at the 
proximal aspect of the third metacarpal bone at the insertion of the 
suspensory ligament (B).
MSCs and PRP (from Global Stem Cell Technology) in 
 combination with NSAIDs was performed by an equine ortho-
pedic  specialist. Both tenogenically induced MSCs and PRP 
were prepared from a 6-year-old German Warmblood horse and 
characterized as previously described (12, 22).
Briefly, 50  ml of peripheral blood was collected from the 
vena jugularis in ethylenediaminetetraacetic acid (EDTA) tubes 
for MSC isolation. Subsequently, the blood was centrifuged at 
1000 × g for 20 min and the buffy coat was collected and diluted 
1:2 with Hanks’ Balanced Salt Solution (HBSS, Life Technologies). 
This suspension was gently layered on an equal amount of Percoll 
(GE Healthcare). After different washing steps with HBSS, 20 mil-
lion peripheral blood mononuclear cells (PBMCs) were seeded 
per T75 flask and cultured until 60% confluency was reached. 
Trypsinization was performed with 0.25% trypsin–EDTA until 
passage 6 (P6) was reached. Going to P7, 0.5 million MSCs were 
seeded in a T75 flask and tenogenically induced by supplement-
ing tendogenic growth factors to the expansion medium until 
80% confluency was reached, and tenogenic differentiation 
markers were upregulated (Gomiero et al., in review). A higher 
passage was used to allow upscaling in future cell manufacturing 
processes, which is considered to be possible thanks to the phe-
notypic stability of PB–MSCs from P5 up to P10 (23, Gomiero et 
al., in review). After trypsinization, all the cells were resuspended 
in 1 ml of DMEM low glucose (Life Technologies) with 10% of 
dimethyl sulfoxide (DMSO, Sigma). The samples were stored 
in −80°C until all quality controls were completed. The latter 
consisted of sterility testing and flow cytometry assessment for 
(stem) cell markers, as previously reported (22, 23).
FIGUre 2 | transverse (encircled lesion area) and longitudinal (arrow in lesion area) ultrasound images of the proximal aspect of the lateral lobe of 
the suspensory ligament performed at T0, T4 (12 weeks), and T5 (16 weeks). At T0, a clear hypo-echoic area could be noticed on both ultrasounds. At T4, only 
limited remaining hypo-echoic areas were noticed, whereas this clearly reduced at T5.
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For PRP preparation, 300  ml of peripheral blood was 
taken in a citrate phosphate dextrose adenine-1 (CPDA-1) 
single blood bag (Terumo®) from the same donor. Platelets 
were purified by means of subsequent centrifugation steps, as 
previously reported (24) until more than 80% platelets were 
obtained at a concentration of more than 100 × 106 platelets 
in 1  ml. Cells and PRP were shipped on dry-ice for clinical 
application. After trypan blue staining, it became clear that 
more than 75% of the tenogenically induced MSCs were viable 
upon injection.
The horse was sedated with 0.04  mg/kg detomidine 
(Domosedan®) and 0.1  mg/ml butorphanol (Turbogesic®) 
intravenously, and the treatment site was aseptically prepared. A 
7.5 MHz linear ultrasound probe was covered with a sterile glove 
to perform the ultrasound-guided intralesional injection. A ster-
ile 21G needle was introduced into the lesion and connected to 
the syringe with the tenogenically induced MSCs (1 ml) and PRP 
(1 ml). After the treatment, a soft protective bandage was applied 
and left on for 1 day, followed by the exact same rehabilitation 
program as described above for the first treatment.
taBLe 3 | evaluation of the proximal suspensory healing by clinical assessment and ultrasound examination at 4 weeks before the injection (T0), the day 
of injection (T1), and every 4 weeks up to week 16 (T2–5).
T0 T1 T2 T3 T4 T5
Lameness score AAEP 2 2 1 0–1 0–1 0
Ultrasound score 1 1 2 3 3 4
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A second intralesional injection with allogeneic tenogenically 
induced MSCs and PRP was performed 12 weeks after the first 
injection in order to stimulate the healing after stagnation.
outcome
Clinical Assessment
Clinical evaluation was performed 4 weeks before injection (T0), 
and at 4-week intervals after the first injection (T1 =  0  weeks, 
T2 = 4 weeks, T3 = 8 weeks, T4 = 12 weeks, T5 = 16 weeks). A 
second injection was performed 12 weeks after the first injection 
at T4. Clinical evaluation was performed according to the AAEP 
scoring system by the same team of veterinarians.
At T0, the horse showed a right front lameness with a Grade 
2/5 consistent in degree in straight lines and more pronounced 
when trotting on a circle to the left on a soft surface (Table 3). 
At T1, 4  weeks after the diagnosis, the horse was treated by a 
first intralesional injection with the combination of peripheral 
blood-derived tenogenically induced MSCs and PRP. At subse-
quent evaluation time point T2, the lameness was reduced to a 
right front lameness with a Grade 1/5 and an improvement in the 
cranial phase of the stride (Table 3). At T3 and T4, the lameness 
was graded 0–1/5, because it was inconsistently apparent and 
difficult to observe.
A second intralesional injection with MSCs and PRP was 
performed at T4, 12 weeks after the first injection. At evaluation 
time point T5, 4 weeks after the second intralesional injection (i.e., 
16 weeks after the first injection), the horse trotted completely 
sound under all circumstances tested (Table 3). Communication 
with the owner revealed that the horse started performing at pre-
vious level (sub Grand Prix) at 32 weeks after the first regenerative 
treatment and is currently still doing so (i.e., 20 weeks later or 
1 year after the first stem cell treatment).
Ultrasound Examination
A score between 0 and 5 for the ultrasound images was given. At 
T0 and T1, the horse received a score 1, which corresponded with 
the initiation of lesion filling with the presence of hypo-echoic 
areas, a moderate diffuse decrease in echogenicity, lacking of a 
parallel fiber pattern and 0–25% fiber alignment (Figure 2). At 
T2, a score of 2 was given, which indicated a gradual filling of 
the lesion with the presence of multiple areas with decreased 
echogenicity, an increased parallel fiber pattern and 25–50% 
fiber alignment. At subsequent evaluation time points, T3 and 
T4, a score of 3 corresponded with a less distinct demarcation 
between injured and uninjured tendon with remaining hypo-
echoic areas, an increased parallel fiber pattern, 25–50% fiber 
alignment and reduced width and thickness. At 4  weeks after 
the second injection (T5), a score of 4 was given, which indicated 
hardly any demarcation between injured and healthy tissue, faint 
hypo-echoic areas, an almost total fiber alignment and very mild 
increased thickness (Figure 2). An overview of the ultrasound 
scores can be found in Table 3.
DIscUssIoN
Proximal suspensory ligament injuries are an important source 
of lameness in performance horses. Because of both soft tissue 
and bone components, the suspensory ligament has a complex 
anatomy, and therefore, diagnosis should be made by multiple 
modalities. A good diagnosis can be made by the combination 
of ultrasound examination and radiology, but often advanced 
imaging, such as nuclear scintigraphy, magnetic resonance imag-
ing, and computed tomography, will be required to detect certain 
types of injury (25).
In this case report, diagnosis was made by ultrasound, radiol-
ogy, and computed tomography. However, no contrast angiogra-
phy was performed, which could have provided more information 
on lesion severity and perfusion. Indeed, contrast angiography 
would have allowed us to distinguish between the normal fat 
and muscle tissue at the origin of the suspensory ligament and a 
lesion of the ligament (26–28). This would have provided more 
detailed information on the extent of the soft tissue lesion and 
should be considered for diagnostic and treatment evaluation 
in future studies. Nevertheless, in the present report, computed 
tomography accurately identified new bone formation that was 
not fully revealed via radiology and ultrasound. In horses with 
a chronic or recurring lameness origination from the proximal 
aspect of the third metacarpal bone, new bone formation at the 
proximal region of insertion of the suspensory ligament, should 
be considered as a differential diagnosis (29).
Since it has been described that uninduced MSCs have the 
ability to form ectopic bone in calcified areas (30), the use of 
tenogenically induced MSCs represented a safe alternative in this 
case report. Nevertheless, larger studies comparing both treat-
ment modalities will have to provide more insights in this matter. 
In addition, treatment after ultrasound-guided intralesional 
injection supports suspensory ligament healing and has a bet-
ter prognosis, compared to conservative therapy, for returning 
to sport activity (2). In the present report, PRP and peripheral 
blood-derived tenogenically induced MSCs were injected 
together, as previously described by our group (12). Since the 
suspensory ligament injury was irresponsive to PRP treatment 
alone (cfr. Patient history) and no control group without PRP 
was used, no conclusions can be made concerning the necessity 
of PRP addition in order to obtain the desired clinical effect. 
However, for degenerative joint disease in horses, a substantial 
improvement of the clinical outcome could be demonstrated 
after PRP addition to allogeneic MSCs (13). This was probably 
October 2015 | Volume 2 | Article 496
Vandenberghe et al. Tenogenically induced MSCs for treatment of desmitis
Frontiers in Veterinary Science | www.frontiersin.org
reFereNces
1. Murray RC, Walters JM, Snart H, Dyson SJ, Parkin TDH. Identification of risk 
factors for lameness in dressage horses. Vet J (2010) 184:27–36. doi:10.1016/j.
tvjl.2009.03.020 
2. Romagnoli N, Rinnovati R, Ricciardi G, Lambertini C, Spinella G, Spadari A. 
Clinical evaluation of intralesional injection of platelet-rich plasma for the 
treatment of proximal suspensory ligament desmitis in horses. J Equine Vet 
Sci (2015) 35:141–6. doi:10.1016/j.jevs.2014.12.011 
3. Nirschl RP. Patterns of failed healing in tendon injury. In: Leadbetter WB, 
Buckwalter JA, Gordon SL, editors. Sports-Induced Inflammation: Clinical and 
Basic Concepts. Park Ridge, IL: American Academy of Orthopaedic Surgeons 
(1990). p. 577–85.
4. Riley G. The pathogenesis of tendinopathy. A molecular perspective. 
Rheumatology (Oxford) (2004) 43:131–42. doi:10.1093/rheumatology/
keg448
5. Bowring B, Chockalingam N. Conservative treatment of tibialis posterior 
tendon dysfunction  –  a review. Foot (2010) 20:18–26. doi:10.1016/j.
foot.2009.11.001 
6. Foland JW, Trotter GW, Powers BE, Wrigley RH, Smith FW. Effect of sodium 
hyaluronate in collagenase-induced superficial digital flexor tendinitis in 
horses. Am J Vet Res (1992) 53:2371–6. 
7. Peers KH, Lysens RJ. Patellar tendinopathy in athletes: current diag-
nostic and therapeutic recommendations. Sports Med (2005) 35:71–87. 
doi:10.2165/00007256-200535010-00006 
8. Spaas JH, Guest DJ, Van de Walle GR. Tendon regeneration in human and 
equine athletes. Sports Med (2012) 42:871–90. doi:10.1007/BF03262300 
9. Dyson S. Proximal suspensory desmitis in the forelimb and the hindlimb. 
Proceedings of the AAEP Annual Convention, 2000 Nov 26–29; San Antonio, 
TX (2000). 46, p. 137–42. 
10. Henninger RW, Bramlage LR, Bailey M, Bertone AL, Weisbrode SE. Effects of 
tendon splitting on experimentally-induced acute equine tendinitis. Vet Comp 
Orthop Traumatol (1992) 5:1–9. 
11. Herthel DJ. Suspensory desmitis therapies. Proceedings of the 12th ACVS 
Veterinary Symposium, 2002 Oct 17–20; San Diego, CA (2002). p. 165–7.
12. Broeckx S, Zimmerman M, Aerts D, Seys B, Suls M, Mariën T, et al. Tenogenesis 
of equine peripheral blood-derived mesenchymal stem cells: in vitro versus 
in vivo. J Tissue Sci Eng (2012) 11:1–5. doi:10.4172/2157-7552.S11-001
13. Broeckx S, Zimmerman M, Corcetti S, Suls M, Mariën T, Ferguson SJ, et al. 
Regenerative therapies for equine denegerative joint disease: a preliminary 
study. PLoS One (2014) 9:e85917. doi:10.1371/journal.pone.0085917 
14. Carrade DD, Affolter VK, Outerbridge CA, Watson JL, Galuppo LD, Buerchler 
S, et  al. Intradermal injections of equine allogeneic umbilical cord-derived 
mesenchymal stem cells are well tolerated and do not elicit immediate or 
delayed hypersensitivity reactions. Cytotherapy (2011) 13:1180–92. doi:10.3
109/14653249.2011.602338 
15. Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL, Librach F, et al. 
Clinicopathologic findings following intra-articular injection of autologous 
and allogeneic placentally derived equine mesenchymal stem cells in horses. 
Cytotherapy (2011) 13:419–30. doi:10.3109/14653249.2010.536213 
16. Broeckx S, Borena BM, Zimmerman M, Marien T, Seys B, Suls M, et  al. 
Intravenous application of allogenic peripheral blood-derived mesenchymal 
stem cells: a safety assessment in 291 equine recipients. Curr Stem Cell Res Ther 
(2014) 9:452–7. doi:10.2174/1574888X09666140220003847 
17. Broeckx S, Suls M, Beerts C, Vandenberghe A, Seys B, Wuertz-Kozak K, et al. 
Allogenic mesenchymal stem cells as a treatment for equine degenerative joint 
disease: a pilot study. Curr Stem Cell Res Ther (2014) 9:497–503. doi:10.2174/1
574888X09666140826110601 
18. Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and 
allogeneic mesenchymal progenitor cells injected into the superficial digital 
flexor tendon of horses: preliminary study. Equine Vet J (2008) 40:178–81. doi
:10.2746/042516408X276942 
19. Ricco S, Renzi S, Del Bue M, Conti V, Merli E, Ramoni R, et al. Allogeneic 
adipose tissue-derived mesenchymal stem cells in combination with platelet 
rich plasma are safe and effective in the therapy of superficial digital flexor 
tendonitis in the horse. Int J Immunopathol Pharmacol (2013) 26:61–8. 
20. Van Loon VJ, Scheffer CJ, Genn HJ, Hoogendoorn AC, Greve JW. Clinical 
follow-up of horses treated with allogeneic equine mesenchymal stem cells 
derived from umbilical cord blood for different tendon and ligament disor-
ders. Vet Q (2014) 34:92–7. doi:10.1080/01652176.2014.949390 
attributed to the stem cell stimulating growth factors that are 
present in PRP. For this reason, the latter substance was added 
to the tenogenically induced MSCs. Further studies will provide 
more clarity on the effect of PRP on MSC-related therapies for 
tendon healing in horses.
It should be mentioned though that at 12  weeks after the 
first treatment, hypo-echoic areas with a discrete demarcation 
between injured and uninjured tendon were still present on the 
ultrasound images. This is in contrast with 11 out of 15 horses 
with suspensory ligament desmitis, which demonstrated only 
faint signs of hypo-echoic areas and hardly any demarcation 
between injured and healthy tissue at 6 weeks post injection (12). 
In this case study, the latter state was only reached at 4 weeks after 
the second injection (i.e., 16 weeks after the first injection). An 
explanation for the noticed discrepancy might be that the present 
case demonstrated new bone formation, which compromised the 
first treatment. Indeed, it has been previously reported that carpal 
osteophytes might result in tendon ruptures (31). Moreover, 
suspensory ligament desmitis has a poor prognosis in general 
(32, 33) and conservative management for 4  months did not 
result in any improvement in this case. Nevertheless, a second 
injection reactivated the healing and resulted in recovery. Since 
it has been demonstrated that autologous MSCs elicit a similar 
immune response than allogeneic MSCs in equine superficial 
digital flexor tendons, no immunogenic hypersensitivity was 
expected nor observed after repeated injections (18). In the 
present case with a chronic suspensory ligament injury, a second 
injection was warranted due to remaining hypo-echoic areas 
and abnormal fibern pattern. Although no reports are available 
describing the influence of repeated MSC injections on chronic 
tendon injuries, repeated MSC treatments of liver fibrosis (34) 
and cardiomyopathies (35, 36) resulted in significantly enhanced 
tissue repair and functionality in comparison to single dose 
treatments. In both organs, reduced fibrosis was at the basis of 
the noticed improvements and this was achieved by remodeling 
of the collagen network, which is a crucial element in chronic 
tendon injury as well (8).
In conclusion, a positive evolution of proximal suspensory 
ligament desmitis could be demonstrated after repeated injec-
tion with allogeneic tenogenically induced MSCs together 
with PRP. However, large placebo-controlled field studies are 
required in order to provide more insights in their regenerative 
capacities and modus operandi. Moreover, follow-up data after 
several years are necessary to confirm the sustainability of the 
repaired tissue.
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